ID   JVM-13
AC   CVCL_1318
SY   JVM 13; JVM13
DR   CLO; CLO_0007046
DR   CLDB; cl2964
DR   CLDB; cl5073
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-3003
DR   BioSample; SAMN01821571
DR   BioSample; SAMN01821641
DR   BioSample; SAMN03471707
DR   DSMZ; ACC-19
DR   DSMZCellDive; ACC-19
DR   ECACC; 96090516
DR   GEO; GSM1266785
DR   GEO; GSM1266786
DR   Wikidata; Q54899190
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3262465;
RX   PubMed=20454443;
RX   PubMed=24362935;
RX   PubMed=25315077;
RX   PubMed=25960936;
RX   PubMed=28196595;
RX   PubMed=29666304;
RX   PubMed=31160637;
WW   https://tcpaportal.org/mclp/
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 58 hours (PubMed=25315077); ~70 hours (DSMZ=ACC-19).
CC   HLA typing: A*02:01,03:01; B*15:01,56:01; C*01:02,03:03; DQA1*01:03,01:03; DQB1*06:03,06:03; DRB1*13:01,03:38 (PubMed=25960936).
CC   HLA typing: A*02:01:01,03:01:01; B*15:01:01,56:01:01; C*01:02:01,03:03:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,06:01; DQA1*01:03:01,01:03:01; DQB1*06:03:01,06:03:01; DRA*01:02:02,01:02:02; DRB1*13:01:01,13:01:01 (DSMZCellDive=ACC-19).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC=CRL-3003; DSMZ=ACC-19; ECACC=96090516
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 9,11
ST   D16S539: 11
ST   D18S51: 14,19
ST   D19S433: 14
ST   D21S11: 29
ST   D2S1338: 18,20
ST   D3S1358: 15,19
ST   D5S818: 11
ST   D7S820: 9
ST   D8S1179: 13,13.2
ST   FGA: 22,24
ST   Penta D: 10
ST   Penta E: 9,10
ST   TH01: 6,7
ST   TPOX: 10,11
ST   vWA: 16,18
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   60-69Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 25
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3262465;
RA   Vaz de Melo J., Foroni L., Brito-Babapulle V., Luzzatto L., Catovsky D.;
RT   "The establishment of cell lines from chronic B cell leukaemias:
RT   evidence of leukaemic origin by karyotypic abnormalities and Ig gene
RT   rearrangement.";
RL   Clin. Exp. Immunol. 73:23-28(1988).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=24362935; DOI=10.1038/nm.3435;
RA   Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chan F.C.,
RA   Meissner B., Bhang H.-E.C., Ruddy D., Kauffmann A., Farsidjani A.,
RA   Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S.,
RA   Dietze K., Dorken B., Steidl C., Tzankov A., Hummel M., Monahan J.,
RA   Morrissey M.P., Fritsch C., Sellers W.R., Cooke V.G., Gascoyne R.D.,
RA   Lenz G., Stegmeier F.;
RT   "Pharmacological and genomic profiling identifies NF-kappaB-targeted
RT   treatment strategies for mantle cell lymphoma.";
RL   Nat. Med. 20:87-92(2014).
//
RX   PubMed=25315077; DOI=10.3109/10428194.2014.970548;
RA   Fogli L.K., Williams M.E., Connors J.M., Reid Y.A., Brown K.,
RA   O'Connor O.A.;
RT   "Development and characterization of a Mantle Cell Lymphoma Cell Bank
RT   in the American Type Culture Collection.";
RL   Leuk. Lymphoma 56:2114-2122(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//